Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
88 Results for "
Curcumin II-d4
" in MedChemExpress (MCE) Product Catalog:
Products (88)
88 Results for "Curcumin II-d4" in MCE Product Catalog:
Cat. No.: HY-N18668
CAS No.: 84775-52-0
Cat. No.: HY-186287
CAS No.: 3061366-74-0
PROTAC DYRK2 degrader-2 is a PROTAC DYRK2 degrader based on curcumin analog A3. It recruits the CRBN E3 ligase to mediate DYRK2 ubiquitination and achieves degradation via the ubiquitin-proteasome system. PROTAC DYRK2 degrader-2 downregulates the expression level of DYRK2 protein in cancer cells. It is applicable to cancer-related research .
Cat. No.: HY-187991
FtsZ-IN-16 is a curcumin derivative and also an inhibitor of XooFtsZ, with an EC50 of 3.74 μg/mL against Xoo. FtsZ-IN-16 targets the FtsZ residues LEU71, GLY74, GLY110 and THR111 of Xanthomonas oryzae pv. oryzae, thereby blocking GTPase (GTPase) activity and polymerization. FtsZ-IN-16 can be used in studies related to rice bacterial blight .
Cat. No.: HY-W010056R
CAS No.: 623-91-6
Category:
Target:
Cat. No.: HY-D2962
Cat. No.: HY-W110707S
CAS No.: 1191245-82-5
Synonyms: Hexadecylamine-d33
Cat. No.: HY-137059
CAS No.: 1217503-60-0
Research Areas:
GO-Y078 is a curcumin (HY-N0005) analog. GO-Y078 activates p38/JNK1/2. GO-Y078 activates the MAPK pathway, Caspase 3/8/9, PARP, AP-1, DR5, and TP53, while inhibiting cIAP-1, XIAP, and NF-κB. GO-Y078 induces sub-G1/G2/M phase arrest and Apoptosis. GO-Y078 impairs angiogenesis. GO-Y078 can be used in research related to osteosarcoma, cervical cancer, oral squamous cell carcinoma, and peritoneal metastasis of gastric cancer [4] .
Cat. No.: HY-183402
CAS No.: 917813-60-6
Synonyms: GO-Y026
Target:
Research Areas:
FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer [4] .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
